Photo of Marshall Posner

Marshall Posner

  • PROFESSOR Medicine, Hematology and Medical Oncology
  • PROFESSOR Otolaryngology
Print ProfilePrint Profile

Certifications

  • Medical Oncology

  • American Board of Internal Medicine

Clinical Focus

  • Adenoid Cystic Carcinoma (ACC)
  • Cancer Prevention
  • Cancer Survivorship
  • Clinical Trials
  • Gum Cancer
  • Head and Neck Cancers
  • Immunotherapy
  • Merkel Cell Tumors
  • Mouth Cancer
  • Nasal Cancer
  • Nasal Cavity Cancer
  • Nasopharyngeal Cancer (NPC)
  • Oral Cavity Cancer
  • Oropharynx Cancer
  • Paranasal Sinus Cancer
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Pharynx Cancer
  • Photodynamic Therapy
  • Salivary Gland Tumors
  • Sinus Cancer
  • Skull Base Tumors
  • Squamous Cell Carcinoma
  • Throat Cancer
  • Thyroid Cancer
  • Thyroid Tumors
  • Tonsil Cancer
  • Vaccines

Education

  • MD, Tufts University

  • Residency, Internal Medicine
    Boston City Hospital

  • Fellowship, Medical Oncology
    Dana Farber Cancer Institute

Biography

    Dr. Marshall Posner is a Professor of Medicine, Medical Director of the Head and Neck Oncology Center, and Associate Director of the Center for Personalized Cancer Therapeutics at the Mount Sinai Medical Center and the Icahn School of Medicine at Mount Sinai. He is also Associate Director for Cancer Clinical Research Infrastructure for the Tisch Cancer Institute.  Dr. Posner has been an advocate for clinical research and multi-disciplinary care in head and neck cancer. He participates in international symposia and on planning committees devoted to advancing clinical care and directing clinical research in head and neck cancer.
    He is a current or past member of the editorial boards of many journals, including the Journal of Clinical Oncology, Annals of Oncology, Oral Oncology, The Oncologist, and Head and Neck, and he serves as an ad hoc reviewer for, among others, The New England Journal of Medicine. Dr. Posner has been a member of the National Institutes of Health Review Committees for the NIH Inter-Institute Program and the Specialized Programs of Research Excellence in Human Cancer, Head & Neck Cancer, and of the National Cancer Institute's Special Emphasis Panel for phase II Contracts. He has published over 220 peer-reviewed basic laboratory and clinical studies, as well as multiple reviews and abstracts. He is an Section Editor for UpToDate and the Oncologist.

    Dr. Posner has a long laboratory and translational research history in viral diseases and immunology and is currently leading research in the biology, immunology and therapy of HPV related oropharyngeal cancer. he holds patents in human monoclonal antibodies for treatment of human viral and bacterial related diseases.

    In the News:
    Dr. Posner discusses HPV-related oral cancer in the New York Times.

    Dr. Posner discusses the warning signs of oral cancer and what to watch out for on the Katie Couric show.

    The ASCO Post features Dr. Posner discussing "Challenges, Progress, and Future Directions in Head and Neck Cancer" (March 1, 2012)

    Dr. Marshall Posner discusses the link between HPV and oropharyngeal cancers in The Daily News feature The Daily Check Up.

Awards

  • 2007 -
    Ninth Warton Visiting Professor, Prince Margaret Hospital

  • 2007 -
    Tisch Award for Clinical Research, Dana-Farber Cancer Institute

  • 1975 -
    Alpha Omega Alpha, Medical Honor Society

Research

HPV and Human Oropharyngeal Cancer

Translational studies to understand the biology and immunology of HPV related oropharyngeal cancer in order to inform therapeutic and preventative therapies in this disease.

Clinical Studies in Head and Neck Cancer

Development of curative therapeutics for patients with HPV positive and negative head and neck cancer, through clinical trials, drug development and translational studies using conventional chemotherapy, novel biotherapeutics vaccines and gene therapies.

Publications

.;.

Bonomi M, Abbott RW, Patsias A, Misiukiewicz K, Demicco EG, Zhang D, Kaufman A, Genden EM, Posner M. Role of human papillomavirus and p16 staining in a patient with head and neck cancer presenting with a synchronous lung nodule: a case report and review of the literature. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Jan; 33(3).

Misiukiewicz K, Gupta V, Bakst R, Posner M. Taxanes in cancer of the head and neck. Anti-cancer drugs 2014 May; 25(5).

D'Souza G, Gross ND, Pai SI, Haddad R, Anderson KS, Rajan S, Gerber J, Gillison ML, Posner MR. Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Aug; 32(23).

Anderson KS, Wong J, D'Souza G, Riemer AB, Lorch J, Haddad R, Pai SI, Longtine J, McClean M, LaBaer J, Kelsey KT, Posner M. Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. British journal of cancer 2011 Jun; 104(12).

Agoston ES, Robinson SJ, Mehra KK, Birch C, Semmel D, Mirkovic J, Haddad RI, Posner MR, Kindelberger D, Krane JF, Brodsky J, Crum CP. Polymerase chain reaction detection of HPV in squamous carcinoma of the oropharynx. American journal of clinical pathology 2010 Jul; 134(1).

Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. The Lancet. Oncology 2013 Mar; 14(3).

Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Hernandez JJ, Bourredjem A, Calais G, Paccagnella A, Hitt R, Pignon JP. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Aug; 31(23).

Yu X, Duval M, Lewis C, Gawron MA, Wang R, Posner MR, Cavacini LA. Impact of IgA constant domain on HIV-1 neutralizing function of monoclonal antibody F425A1g8. Journal of immunology (Baltimore, Md. : 1950) 2013 Jan; 190(1).

Haddad RI, Tishler RB, Norris C, Goguen L, Balboni TA, Costello R, Wirth L, Lorch J, Andreozzi B, Annino D, Posner MR. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Sep; 27(27).

Limaye SA, Posner MR, Krane JF, Fonfria M, Lorch JH, Dillon DA, Shreenivas AV, Tishler RB, Haddad RI. Trastuzumab for the treatment of salivary duct carcinoma. The oncologist 2013; 18(3).

Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. The Lancet. Oncology 2011 Feb; 12(2).

Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. The Lancet. Oncology 2011 Feb; 12(2).

Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. The Lancet. Oncology 2011 Feb; 12(2).

Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ, Haddad RI, Cullen KJ. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011 May; 22(5).

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Posner during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting:

  • CEL-SCI; Eisai Inc.; Merck Serono

Royalty Payments:

  • sanofi-aventis

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Promedior

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Insurance Information

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Edit profile in Sinai Central

Ruttenberg Treatment Center

1470 Madison Avenue
3rd floor
New York, NY 10029

Tel: 212-241-6756
Fax: 212-241-5599
Get Directions

Office Hours:
  • Monday 9:00am - 5:00pm
  • Tuesday 9:00am - 5:00pm
  • Wednesday 9:00am - 5:00pm
  • Thursday 9:00am - 5:00pm
  • Friday 9:00am - 5:00pm
Insurance Plans
  • 1199
  • Access Meicare
  • Aetna
  • Affinity
  • Amerigroup
  • AmidaCare
  • Cigna
  • Empire Blue Cross/Blue Shield
  • Fidelis
  • GHI
  • Health Insurance Plan (HIP)
  • HealthFirst
  • Healthfirst
  • Humana
  • Island Group
  • Magnacare
  • Medicaid of New York
  • Medicare
  • MetroPlus Health Plan
  • MultiPlan, Inc.
  • Oxford Health Plans
  • United Healthcare
  • VNS Medicare
  • WellCare of New York, Inc.
Payment Methods
  • Master Card
  • Visa
  • American Express
  • Discover
  • Personal Check
  • Cash